Episode 485: Anti-inflammatories for the treatment of community-treated COVID
In episode 485, Mike and James go over a couple of COVID trials that show two different anti-inflammatories – colchicine and inhaled budesonide – seem to have an effect on reducing hospitalizations or urgent care visits.
Show Notes
1) Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial
Lancet Respir Med. 2021 May 27;S2213-2600(21)00222-8.doi: 10.1016/S2213-2600(21)00222-8.
2) Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial
Lancet Respir Med. 2021 Jul;9(7):763-772. doi: 10.1016/S2213-2600(21)00160-0.Epub 2021 Apr 9.
Listening to this episode is for premium podcast members only. If you already have a membership, login to your account. If you aren't yet a premium subscriber, sign up today!
